Poolbeg Pharma PLC (LON:POLB – Get Free Report)’s stock price rose 12.8% during mid-day trading on Friday . The company traded as high as GBX 5.30 ($0.07) and last traded at GBX 5.30 ($0.07). Approximately 1,229,697 shares changed hands during trading, a decline of 81% from the average daily volume of 6,431,729 shares. The stock had previously closed at GBX 4.70 ($0.06).
Wall Street Analyst Weigh In
Separately, Shore Capital restated a “house stock” rating on shares of Poolbeg Pharma in a report on Thursday, January 2nd.
Check Out Our Latest Analysis on POLB
Poolbeg Pharma Trading Up 16.0 %
Poolbeg Pharma Company Profile
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.
Read More
- Five stocks we like better than Poolbeg Pharma
- ESG Stocks, What Investors Should Know
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- NYSE Stocks Give Investors a Variety of Quality Options
- 3 Buy-and-Hold Stocks for Long-Term Growth
- Learn Technical Analysis Skills to Master the Stock Market
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.